Shared on30 Aug 25Fair value Decreased 15%
Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.
Shared on10 Aug 25Fair value Decreased 23%
Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.
Shared on24 Apr 25Fair value Decreased 27%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.
Shared on17 Apr 25Fair value Decreased 4.19%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 28%
AnalystConsensusTarget has increased profit margin from 12.2% to 14.7%, decreased future PE multiple from 20.0x to 17.1x and increased discount rate from 9.9% to 11.0%.